Revenue
Cost
Profit
| Item | Category | Value | YoY |
|---|---|---|---|
| Net sales | revenue | 9.02B | 8.74% |
| Other non-operating income, net | revenue | 121.00M | 68.06% |
| Reportable segment operating profit | profit | 1.46B | -11.06% |
| Cost of products sold, excluding amortization of intangible assets | cost | 3.26B | 17.34% |
| Selling, general, and administrative expense | cost | 2.96B | 8.80% |
| Research and development expense | cost | 722.00M | 6.96% |
| Amortization of intangible assets | cost | 441.00M | 6.01% |
| Restructuring charges, net | cost | 77.00M | 79.07% |
| Certain litigation charges, net | cost | 62.00M | 181.82% |
| Other operating income (expense), net | revenue | 35.00M | -8.00% |
| Aggregate | revenue | 1.58B | -7.80% |
| Income before income taxes | profit | 1.40B | -8.83% |
| Interest expense, net | cost | 181.00M | 1.12% |
| Net income | profit | 1.15B | -11.74% |
| Income tax provision | cost | 254.00M | 7.17% |
| Net income attributable to medtronic | profit | 1.14B | -11.67% |
| Net income (loss) attributable to noncontrolling interest | cost | 6.00M | -33.33% |
| Segment | Value | YoY |
|---|---|---|
| Cardiovascular | 3.46B | 13.83% |
| Neuroscience Group | 2.56B | 4.07% |
| Medical Surgical | 2.17B | 4.87% |
| Diabetes Group | 796.00M | 14.70% |
| Other Operating | 32.00M | 0.00% |
| Others | 1.00M |
| Segment | Value | YoY |
|---|---|---|
| UNITED STATES | 4.49B | 6.04% |
| Total Other Countries, Excluding United States and Ireland | 4.49B | 11.45% |
| IRELAND | 36.00M | 28.57% |
| Item | Category | Value | YoY |
|---|---|---|---|
| Investments | assets | 7.24B | |
| Accounts receivable, less allowances and credit losses of $207 and $199, respectively | assets | 6.36B | |
| Inventories | assets | 6.31B | |
| Other current assets | assets | 3.02B | |
| Cash and cash equivalents | assets | 1.15B | |
| Total current assets | assets | 24.07B | |
| Goodwill | assets | 41.89B | |
| Other intangible assets, net | assets | 10.34B | |
| Property, plant, and equipment, net | assets | 7.18B | |
| Other assets | assets | 4.04B | |
| Tax assets | assets | 3.97B | |
| Total assets | assets | 91.48B | |
| Total equity | liabilities | 49.20B | |
| Total liabilities | liabilities | 42.29B | |
| Noncontrolling interests | liabilities | 211.00M | |
| Accumulated other comprehensive loss | equity | 4.33B | |
| Total shareholders’ equity | equity | 48.98B | |
| Long-term debt | liabilities | 27.88B | |
| Total current liabilities | liabilities | 9.49B | |
| Other liabilities | liabilities | 1.77B | |
| Accrued income taxes | liabilities | 1.59B | |
| Accrued compensation and retirement benefits | liabilities | 1.19B | |
| Deferred tax liabilities | liabilities | 365.00M | |
| Aggregate | equity | 53.31B | |
| Other accrued expenses | liabilities | 3.50B | |
| Accrued compensation | liabilities | 2.58B | |
| Accounts payable | liabilities | 2.57B | |
| Accrued income taxes | liabilities | 650.00M | |
| Current debt obligations | liabilities | 191.00M | |
| Retained earnings | equity | 32.30B | |
| Additional paid-in capital | equity | 21.01B |
| Item | Value |
|---|---|
| Net income | 3.58B |
| Depreciation and amortization | 2.24B |
| Stock-based compensation | 362.00M |
| Other noncash income (expense) | 280.00M |
| Provision for credit losses | 102.00M |
| Increase (decrease) in accounts and notes receivable | 87.00M |
| Deferred income taxes | 59.00M |
| Accounts payable and accrued liabilities | -77.00M |
| Increase (decrease) in inventories | -803.00M |
| Increase (decrease) in other operating assets and liabilities, net | -1.07B |
| Item | Value |
|---|---|
| Proceeds from sale, maturity and collection of investments | 5.98B |
| Payment for (proceeds from) other investing activity | -10.00M |
| Payments to acquire property, plant, and equipment | -1.42B |
| Payments to acquire investments | -6.57B |
| Item | Value |
|---|---|
| Issuance of long-term debt | 1.75B |
| Issuance of ordinary shares | 419.00M |
| Change in current debt obligations, net | 173.00M |
| Other financing activities, net | 60.00M |
| Payments for repurchase of common stock | -600.00M |
| Payments of ordinary dividends, common stock | -2.73B |
| Repayments of long-term debt | -2.93B |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 2.22B |
| Cash and cash equivalents, end of period | 1.15B |
Instantly decode complex 10-K and 10-Q data. Explore interactive Sankey diagrams for income and balance sheets, and intuitive waterfall charts for cash flows.
Search for a company and select a report on the left panel.
Request Stock Support